title: Risk factors for cytomegalovirus pneumonia following allogeneic bone marrow transplantation after prophylaxis with intravenous immunoglobulin.
authors.affiliation: University of Florida, Gainesville.
authors.forename: J
authors.initials: J
authors.lastname: Krischer
authors.forename: G
authors.initials: G
authors.lastname: Elfenbein
authors.forename: R
authors.initials: R
authors.lastname: Babington
authors.forename: R
authors.initials: R
authors.lastname: Hong
authors.forename: J
authors.initials: J
authors.lastname: Jansen
authors.forename: H
authors.initials: H
authors.lastname: Lazarus
authors.forename: E
authors.initials: E
authors.lastname: Winton
authors.forename: K
authors.initials: K
authors.lastname: Rand
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D015994:Incidence; D007223:Infant; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D011024:Pneumonia, Viral / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D016016:Proportional Hazards Models; D011658:Pulmonary Fibrosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D012307:Risk Factors; D015996:Survival Rate; D014916:Whole-Body Irradiation / Q000009:adverse effects
chemical_list: D016756:Immunoglobulins, Intravenous